This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): Avalox, Havelox, moxifloxacin HCl, BAY 12-8039
Description: Avelox (Moxifloxacin) is a broad spectrum quinolone antibiotic that acts against a wide range of Gram-positive and Gram-negative bacteria. The bactericidal activities of Avelox results from the inhibition of Topoisomerase II (DNA gyrase) and IV, required for bacterial DNA replication, transcription, repair, and recombination.
Moxifloxacin exhibits good activity against enteric Gram-(-) bacteria, Streptococcus pnuemoniae, atypicals, and Haemophilus pneumoniae; moderate activity against methicillin sensitive Staphylococcus pneumoniae and anaerobes; and poor activity against enterococci.
Deal Structure: Avelox was originally developed by Bayer AG.
In 2003, Bayer and Shionogi entered into an agreement that provides Shionogi with exclusive Japanese marketing rights for Avelox. According to the terms of the agreement, Bayer Yakuhin will continue to hold the drugs registration and Shionogi will exclusively market the product.
In October 2004, Schering-Plough announced that it acquired exclusive rights from Bayer AG to market, sell and distribute Avelox in the United States and Puerto Rico.
In March 2009, Merck & Co and Schering-Plough announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Under the terms of the agreement, Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Merck & Co and...See full deal structure in Biomedtracker
Partners: Bayer AG
Pink Sheet Bayer Avelox Phase IV Commitments
Additional information available to subscribers only: